← FDA DRUG APPROVALS

FDA NDA · NDA050007

VIBRAMYCIN

Sponsor: PFIZER

APPLICATION
NDA050007
TYPE
NDA
ORIGINAL APPROVAL
1967-12-05
LATEST ACTION
2025-08-08
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

VIBRAMYCIN · ReferenceDiscontinued
DOXYCYCLINE HYCLATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE · ORAL
VIBRAMYCIN · ReferenceDiscontinued
DOXYCYCLINE HYCLATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE · ORAL

Approval history

2025-08-08Labeling · Supplement 40 · standardLabelAP
2025-03-31Labeling · Supplement 39 · standardLabelAP
2019-12-20Labeling · Supplement 34 · standardLabelAP
2018-12-03Labeling · Supplement 33 · standardLabelAP
2017-07-26Labeling · Supplement 32 · standardLabelAP
2016-12-21Labeling · Supplement 31 · standardLabelAP
2016-03-31Labeling · Supplement 30 · standardLabelAP
2015-05-05Manufacturing (CMC) · Supplement 29LabelAP
2014-10-28Manufacturing (CMC) · Supplement 28AP
2014-09-12Labeling · Supplement 27 · standardLabelAP
2013-09-04Labeling · Supplement 26 · standardLetterAP
2013-04-29Labeling · Supplement 25 · standardLetterAP
2011-05-11Labeling · Supplement 23 · standardLabelAP
2008-02-06Labeling · Supplement 20 · standardLetterAP
2004-03-12Labeling · Supplement 16 · standardLetterAP
2002-06-18Labeling · Supplement 14 · standardLetterAP
2002-05-15Manufacturing (CMC) · Supplement 15AP
2000-03-02Manufacturing (CMC) · Supplement 13AP
1992-12-15Efficacy · Supplement 12AP
1992-05-11Labeling · Supplement 10AP
1992-05-11Labeling · Supplement 11AP
1991-08-23Labeling · Supplement 8AP
1991-07-24Manufacturing (CMC) · Supplement 9AP
1967-12-05UNKNOWN · Original · unknownAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →